71 related articles for article (PubMed ID: 27890465)
1. Palbociclib improves survival in advanced breast cancer.
Burki TK
Lancet Oncol; 2017 Jan; 18(1):e1. PubMed ID: 27890465
[No Abstract] [Full Text] [Related]
2. Palbociclib and Letrozole in Advanced Breast Cancer.
Finn RS; Martin M; Rugo HS; Jones S; Im SA; Gelmon K; Harbeck N; Lipatov ON; Walshe JM; Moulder S; Gauthier E; Lu DR; Randolph S; Diéras V; Slamon DJ
N Engl J Med; 2016 Nov; 375(20):1925-1936. PubMed ID: 27959613
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
4. A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6.
Sherr CJ
N Engl J Med; 2016 Nov; 375(20):1920-1923. PubMed ID: 27959598
[No Abstract] [Full Text] [Related]
5. Palbociclib: A new hope in the treatment of breast cancer.
Palanisamy RP
J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
[TBL] [Abstract][Full Text] [Related]
6. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
Cardoso F; Costa A; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Bhattacharyya G; Biganzoli L; Cardoso MJ; Carey L; Corneliussen-James D; Curigliano G; Dieras V; El Saghir N; Eniu A; Fallowfield L; Fenech D; Francis P; Gelmon K; Gennari A; Harbeck N; Hudis C; Kaufman B; Krop I; Mayer M; Meijer H; Mertz S; Ohno S; Pagani O; Papadopoulos E; Peccatori F; Penault-Llorca F; Piccart MJ; Pierga JY; Rugo H; Shockney L; Sledge G; Swain S; Thomssen C; Tutt A; Vorobiof D; Xu B; Norton L; Winer E
Breast; 2017 Feb; 31():244-259. PubMed ID: 27927580
[No Abstract] [Full Text] [Related]
7. Metastatic breast cancer: focus on endocrine sensitivity.
Cristofanilli M
Lancet; 2016 Dec; 388(10063):2961-2962. PubMed ID: 27908455
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra K; Schwenkglenks M; Dedes KJ
Breast Cancer Res Treat; 2017 Jun; 163(3):635. PubMed ID: 28321586
[No Abstract] [Full Text] [Related]
9. Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Rocca A; Schirone A; Maltoni R; Bravaccini S; Cecconetto L; Farolfi A; Bronte G; Andreis D
Ther Adv Med Oncol; 2017 Feb; 9(2):83-105. PubMed ID: 28203301
[TBL] [Abstract][Full Text] [Related]
10. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot X; Burris H; Petersen JA; Stanzel S; Strasak A; Patre M; Ellis P
J Clin Oncol; 2017 Jan; 35(2):141-148. PubMed ID: 28056202
[TBL] [Abstract][Full Text] [Related]
12. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.
Jiralerspong S; Goodwin PJ
J Clin Oncol; 2016 Dec; 34(35):4203-4216. PubMed ID: 27903149
[TBL] [Abstract][Full Text] [Related]
13. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Ma CX; Gao F; Luo J; Northfelt DW; Goetz M; Forero A; Hoog J; Naughton M; Ademuyiwa F; Suresh R; Anderson KS; Margenthaler J; Aft R; Hobday T; Moynihan T; Gillanders W; Cyr A; Eberlein TJ; Hieken T; Krontiras H; Guo Z; Lee MV; Spies NC; Skidmore ZL; Griffith OL; Griffith M; Thomas S; Bumb C; Vij K; Bartlett CH; Koehler M; Al-Kateb H; Sanati S; Ellis MJ
Clin Cancer Res; 2017 Aug; 23(15):4055-4065. PubMed ID: 28270497
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.
Mamiya H; Tahara RK; Tolaney SM; Choudhry NK; Najafzadeh M
Ann Oncol; 2017 Aug; 28(8):1825-1831. PubMed ID: 28472324
[TBL] [Abstract][Full Text] [Related]
15. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
16. Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.
Selli C; Dixon JM; Sims AH
Breast Cancer Res; 2016 Dec; 18(1):118. PubMed ID: 27903276
[TBL] [Abstract][Full Text] [Related]
17. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
18. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
Sammons SL; Topping DL; Blackwell KL
Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Kim ES; Scott LJ
Target Oncol; 2017 Jun; 12(3):373-383. PubMed ID: 28488183
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]